KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Accounts Payables (2016 - 2025)

Fulgent Genetics' Accounts Payables history spans 10 years, with the latest figure at $18.7 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 1.58% year-over-year to $18.7 million; the TTM value through Dec 2025 reached $18.7 million, up 1.58%, while the annual FY2025 figure was $18.7 million, 1.58% up from the prior year.
  • Accounts Payables for Q4 2025 was $18.7 million at Fulgent Genetics, up from $18.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $37.1 million in Q2 2022 and bottomed at $14.5 million in Q3 2022.
  • The 5-year median for Accounts Payables is $19.3 million (2024), against an average of $20.1 million.
  • The largest annual shift saw Accounts Payables skyrocketed 510.86% in 2021 before it crashed 44.47% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $20.5 million in 2021, then grew by 12.68% to $23.1 million in 2022, then crashed by 33.49% to $15.4 million in 2023, then rose by 19.56% to $18.4 million in 2024, then grew by 1.58% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Accounts Payables are $18.7 million (Q4 2025), $18.1 million (Q3 2025), and $18.9 million (Q2 2025).